- Email: [email protected]
CARG tool or VES-13 predict grade 3 + toxicities in men undergoing chemotherapy for metastatic prostate cancer?
2013 SIOG Poster Abstracts
Results: Results: Median age of 72 years with ECOG Status 1 was seen in 88% patients median PSA value was seen as 138 ng/ml, 10 600. 66% patients in both arms had measurable disease. Image:
S37
Objectives: To examine whether either the Hurria/CARG tool or VES-13 predicts grade 3+ toxicity in men with mCRPC undergoing chemotherapy. Methods: Men aged 65 + with mCRPC starting first-line or secondline chemotherapy were enrolled in this prospective observational pilot study. At baseline, along with sociodemographic and clinical information, the VES-13 and Hurria/CARG tools were administered to patients. Toxicity was captured at the end of each cycle of chemotherapy using the Common Terminology Criteria for Adverse Events version 4. Descriptive statistics and chi-square tests were performed to examine relationships between the Hurria/CARG tool (collapsed into 3 risk groups) and the VES-13 (b3 or 3 +) and the development of grade 3+ toxicity in any cycle of chemotherapy. Results: 48 patients (mean age 75, median prostate-specific antigen level 135) have been accrued, with the majority receiving Docetaxel 75 mg/ m^2 q3weekly. Granulocyte-colony stimulating factors were not used. At baseline, 23 patients (49%) were frail by VES-13 criteria and 26%, 38%, and 36% were low, moderate, and high risk of grade 3+ toxicity by the Hurria/ CARG tool, respectively. Frailty tended to increase with higher scores on the Hurria/CARG tool, such that 33%, 41%, and 71% of low, moderate, and high risk patients were frail, respectively. 3 patients (6%) developed grade 3+ toxicity. 1 non-frail patient developed grade 3+ toxicity compared to 2 frail patients (4% versus 9%). Using the Hurria/CARG tool, 0, 0, and 3 (18%) of patients in the low, moderate, and high risk groups developed grade 3+ toxicity. There were 2 deaths while on study, neither of which was related to chemotherapy. Conclusion: Although our sample size is small and few men developed grade 3+ toxicity, this study provides preliminary validation of the predictive ability of the Hurria/CARG tool in a homogeneous population of older men with mCRPC undergoing chemotherapy. The Hurria/CARG tool appears superior to the VES-13, but further validation work with both measures and a larger sample size is warranted. Disclosure of Interest: None Declared
Conclusion: Addition of VT-12 improves Response, duration of Response along with 1 year Survival which are statistically significant; toxicities are also significantly.The efficacy and control of toxicity and easy to administer makes this an attractive combination. Disclosure of Interest: None Declared Keywords: Clinical trials, Drug development, Longevity, Prostate doi:10.1016/j.jgo.2013.09.030
Track 1 - Solid Tumours in the Elderly Prostate, bladder, kidney cancer in eldery patients P027 Does the hurria/CARG tool or VES-13 predict grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer? S. Alibhai1,2,3,*, T. Manokumar1, S. Aziz1, F. Rizvi1, H. Breunis1, H. Gulamhusein1, N. Timilshina3, I. Tannock1,2, A. Joshua1,2. 1Princess Margaret Cancer Centre; 2University of Toronto; 3University Health Network, Toronto, Canada Introduction: Although treatment of metastatic castration-resistant prostate cancer (mCRPC) with chemotherapy improves disease control and survival in older men, it is associated with significant toxicity. Since the absolute survival benefits of chemotherapy are modest, tools that help select men who are more or less likely to develop toxicity may aid clinical decision-making. Two promising tools are the Hurria/Cancer and Aging Research Group (CARG) tool and the Vulnerable Elders Survey-13 (VES-13).
Keywords: Prostate doi:10.1016/j.jgo.2013.09.031
Track 1 - Solid Tumours in the Elderly Prostate, bladder, kidney cancer in eldery patients P028 Effectiveness of docetaxel in elderly metastatic castration-resistant prostate cancer patients (MCRPC) A. Simas*, N. Sousa, F. Carneiro, M. Abreu, C. Faustino, R. Begonha, J. Mauricio. IPO- Porto, Porto, Portugal Introduction: Prostate cancer is a disease of older men as 70% of men with prostate cancer are diagnosed after the age of 65. Docetaxel is the first line chemotherapy choice for mCRPC, for which the registration phase III trial included 20% patients aged over 75. Objectives: Our study was designed to assess the effectiveness of Docetaxel in mCRPC patients aged ≥ 75. Methods: Retrospective cohort of a consecutive series of mCRPC patients treated with Docetaxel at a single comprehensive cancer center. Patients were included if age at first cycle of Docetaxel was equal to or greater than 75 years, Docetaxel was the first chemotherapy for mCRPC, had received no prior chemotherapy regimen and their treatment was delivered outside a clinical trial. Patient and tumor characteristics were retrieved in a standardized collection form, as were treatment delivery and tolerability (adverse events grade ≥ 3 and serious adverse events were recorded). Overall survival (OS) was the main effectiveness outcome (defined as the time between day 1 of Docetaxel and death or last assessment).
Results: Results: Median age of 72 years with ECOG Status 1 was seen in 88% patients median PSA value was seen as 138 ng/ml, 10 600. 66% patients in both arms had measurable disease. Image:
S37
Objectives: To examine whether either the Hurria/CARG tool or VES-13 predicts grade 3+ toxicity in men with mCRPC undergoing chemotherapy. Methods: Men aged 65 + with mCRPC starting first-line or secondline chemotherapy were enrolled in this prospective observational pilot study. At baseline, along with sociodemographic and clinical information, the VES-13 and Hurria/CARG tools were administered to patients. Toxicity was captured at the end of each cycle of chemotherapy using the Common Terminology Criteria for Adverse Events version 4. Descriptive statistics and chi-square tests were performed to examine relationships between the Hurria/CARG tool (collapsed into 3 risk groups) and the VES-13 (b3 or 3 +) and the development of grade 3+ toxicity in any cycle of chemotherapy. Results: 48 patients (mean age 75, median prostate-specific antigen level 135) have been accrued, with the majority receiving Docetaxel 75 mg/ m^2 q3weekly. Granulocyte-colony stimulating factors were not used. At baseline, 23 patients (49%) were frail by VES-13 criteria and 26%, 38%, and 36% were low, moderate, and high risk of grade 3+ toxicity by the Hurria/ CARG tool, respectively. Frailty tended to increase with higher scores on the Hurria/CARG tool, such that 33%, 41%, and 71% of low, moderate, and high risk patients were frail, respectively. 3 patients (6%) developed grade 3+ toxicity. 1 non-frail patient developed grade 3+ toxicity compared to 2 frail patients (4% versus 9%). Using the Hurria/CARG tool, 0, 0, and 3 (18%) of patients in the low, moderate, and high risk groups developed grade 3+ toxicity. There were 2 deaths while on study, neither of which was related to chemotherapy. Conclusion: Although our sample size is small and few men developed grade 3+ toxicity, this study provides preliminary validation of the predictive ability of the Hurria/CARG tool in a homogeneous population of older men with mCRPC undergoing chemotherapy. The Hurria/CARG tool appears superior to the VES-13, but further validation work with both measures and a larger sample size is warranted. Disclosure of Interest: None Declared
Conclusion: Addition of VT-12 improves Response, duration of Response along with 1 year Survival which are statistically significant; toxicities are also significantly.The efficacy and control of toxicity and easy to administer makes this an attractive combination. Disclosure of Interest: None Declared Keywords: Clinical trials, Drug development, Longevity, Prostate doi:10.1016/j.jgo.2013.09.030
Track 1 - Solid Tumours in the Elderly Prostate, bladder, kidney cancer in eldery patients P027 Does the hurria/CARG tool or VES-13 predict grade 3+ toxicities in men undergoing chemotherapy for metastatic prostate cancer? S. Alibhai1,2,3,*, T. Manokumar1, S. Aziz1, F. Rizvi1, H. Breunis1, H. Gulamhusein1, N. Timilshina3, I. Tannock1,2, A. Joshua1,2. 1Princess Margaret Cancer Centre; 2University of Toronto; 3University Health Network, Toronto, Canada Introduction: Although treatment of metastatic castration-resistant prostate cancer (mCRPC) with chemotherapy improves disease control and survival in older men, it is associated with significant toxicity. Since the absolute survival benefits of chemotherapy are modest, tools that help select men who are more or less likely to develop toxicity may aid clinical decision-making. Two promising tools are the Hurria/Cancer and Aging Research Group (CARG) tool and the Vulnerable Elders Survey-13 (VES-13).
Keywords: Prostate doi:10.1016/j.jgo.2013.09.031
Track 1 - Solid Tumours in the Elderly Prostate, bladder, kidney cancer in eldery patients P028 Effectiveness of docetaxel in elderly metastatic castration-resistant prostate cancer patients (MCRPC) A. Simas*, N. Sousa, F. Carneiro, M. Abreu, C. Faustino, R. Begonha, J. Mauricio. IPO- Porto, Porto, Portugal Introduction: Prostate cancer is a disease of older men as 70% of men with prostate cancer are diagnosed after the age of 65. Docetaxel is the first line chemotherapy choice for mCRPC, for which the registration phase III trial included 20% patients aged over 75. Objectives: Our study was designed to assess the effectiveness of Docetaxel in mCRPC patients aged ≥ 75. Methods: Retrospective cohort of a consecutive series of mCRPC patients treated with Docetaxel at a single comprehensive cancer center. Patients were included if age at first cycle of Docetaxel was equal to or greater than 75 years, Docetaxel was the first chemotherapy for mCRPC, had received no prior chemotherapy regimen and their treatment was delivered outside a clinical trial. Patient and tumor characteristics were retrieved in a standardized collection form, as were treatment delivery and tolerability (adverse events grade ≥ 3 and serious adverse events were recorded). Overall survival (OS) was the main effectiveness outcome (defined as the time between day 1 of Docetaxel and death or last assessment).